| Sunday 28/01/2024 |
| 13:00 | Registration |
|
| 14:45 | Opening Remarks |
Dr Klemens HOEGENAUER (NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland)
Dr Karl Heinz KRAWINKLER (NOVARTIS PHARMA AG DEVELOPMENT, Basel, Switzerland)
Dr Antonia F. STEPAN (F. HOFFMANN-LA ROCHE LTD, Basel, Switzerland) |
| 14:59 | Recent Developments in Synthetic Methodologies and their Impact |
|
| Session Chair |
Dr Fabrice GALLOU
(NOVARTIS PHARMA, Basel, Switzerland) |
| 15:00 | Organic Reactions in Aqueous Medium enabled by Surfactants (PL01) |
Dr Niginia BORLINGHAUS
(UNIVERSITY OF KONSTANZ, Konstanz, Germany) |
| 15:30 | Reagents and Catalysts with Translational Potential (PL02) |
Dr Josep CORNELLA COSTA
(MAX PLANCK INSTITUTE FOR COAL RESEARCH, Mülheim an der Ruhr, Germany) |
| 16:00 | Coffee Break |
|
| 16:30 | From Batch to Flow: Advancing Synthetic Organic Chemistry through Technological Innovation (PL03) |
Prof. Timothy NOËL
(UNIVERSITY OF AMSTERDAM, Amsterdam, The Netherlands) |
| 17:00 | Chemo-Biocatalytic Processes Enabled by a Continuous Flow Set Up (PL04) |
Prof. Francesca PARADISI
(UNIVERSITY OF BERN, Bern, Switzerland) |
| 17:30 | Break |
|
| 17:45 | New Catalytic Approaches for Simplifying Complex Molecule Synthesis (KL01) |
Prof. Darren J. DIXON
(UNIVERSITY OF OXFORD, Oxford, United Kingdom) |
| 18:45 | Welcome Reception, Sponsored by abcr |
|
| 20:15 | End of the day |
|
| Monday 29/01/2024 |
| From Underground to Mainstream: Neglected and Novel, Emerging Functional Groups for Drug Discovery |
|
| Session Chair |
Dr Ulrich LÜCKING
(FORX THERAPEUTICS, Basel, Switzerland) |
| 08:30 | Boron Based Heterocycles and their Application in Drug Discovery (PL05) |
Prof. Bhaskar DAS
(LONG ISLAND UNIVERSITY, Brooklyn, United States) |
| 09:00 | “Magic Chloro”: Profound Effects of the Chlorine Atom in Drug Discovery (PL06) |
Dr Yoshihiro ISHIHARA
(VIVIDION THERAPEUTICS, San Diego, United States) |
| 09:30 | Coffee Break |
|
| 10:00 | Deuterium in Drug Design: From Deuterium Switch to De Novo Drug Discovery (PL07) |
Prof. Tracey PIRALI
(UNIVERSITY OF PIEMONTE ORIENTALE, Novara, Italy) |
| 10:30 | New Functional Groups for Synthetic and Discovery Chemistry (PL08) |
Prof. Michael WILLIS
(UNIVERSITY OF OXFORD, Oxford, United Kingdom) |
| 11:00 | Outdoor Networking Activities |
|
| 16:00 | Networking Break |
|
| 16:15 | In Silico Prediction of Phase I and II Metabolism: Guiding Optimisation of Drug Metabolism
o_BRCompany Workshop by Optibriumc_BR |
Dr Matthew SEGALL
(OPTIBRIUM LTD, Cambridge, United Kingdom) |
| Latest Advances and Approaches in Bioconjugation Drug Discovery |
|
| Session Chair |
Dr Karl Heinz KRAWINKLER
(NOVARTIS PHARMA AG DEVELOPMENT, Basel, Switzerland) |
| 17:00 | Bicyclic Peptides as a Novel Therapeutic Modality (PL09) |
Dr Philip MURRAY (BICYCLE THERAPEUTICS, Cambridge, United Kingdom)
(SOPLVIAS AG (WAS FUJIFILM)) |
| 17:30 | Next-Generation Bioconjugates for Intra- and Extracellular Targeting (PL10) |
Prof. Christian HACKENBERGER
(FMP BERLIN, Berlin, Germany) |
| 18:00 | Coffee Break |
|
| 18:30 | Creating Next-Generation Biotherapeutics Using Novel Chemistry Platform Technologies (PL11) |
Dr Vijaya R. PATTABIRAMAN
(BRIGHT PEAK THERAPEUTICS, Basel, Switzerland) |
| 19:00 | Exploring the Versatility of Covalent and Supramolecular Bioconjugation in ADC and AOC (PL12) |
Dr Alain WAGNER
(CNRS/UNIVERSITY OF STRASBOURG, Illkirch, France) |
| 19:30 | Poster Session 1 (odd numbers) |
|
| 20:30 | End of the Poster Session |
|
| Tuesday 30/01/2024 |
| Human Dose Prediction in the Discovery Space |
|
| Session Chair |
Dr Holger FISCHER
(F. HOFFMANN-LA ROCHE LTD., BASEL, Switzerland) |
| 08:30 | Early Human Dose Predictions in Lead Optimization (PL13) |
Dr Johan BYLUND
(CTC CLINICAL TRIAL CONSULTANTS AB, Uppsala, Sweden) |
| 09:00 | Early Human Dose Prediction & Machine Learning Models - Can We Impact Lead Selection? (PL14) |
Dr Gregori GEREBTZOFF
(NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH, Basel, Switzerland) |
| 09:30 | Coffee Break |
|
| 10:00 | SwiftPK: Development and Implementation of a High Throughput PBPK/PD Framework to Inform Drug Selection in Early Drug Discovery (PL15) |
Dr Andres OLIVARES
(F. HOFFMANN-LA ROCHE, Basel, Switzerland) |
| 10:30 | Predicting Human Exposure and Dose of Compounds Targeting the Brain (PL16) |
Dr Nicola COLCLOUGH
(ASTRAZENECA, Cambridge, United Kingdom) |
| 11:00 | Outdoor Networking Activities |
|
| 15:30 | Networking Break |
|
| Antiviral Drug Discovery |
|
| Session Chair |
Dr Dafydd OWEN
(PFIZER, Cambridge, United States) |
| 16:30 | Discovery, Chemistry, and Preclinical Development of Pritelivir, a Novel Option for Acyclovir-Resistant Herpes Simplex Virus Infections (PL17) |
Dr Alexander BIRKMANN
(AICURIS ANTI-INFECTIVE CURES AG, Wuppertal, Germany) |
| 17:00 | Targeting Viral RNA Degradation Via Small Molecules As a Novel Antiviral Strategy to Achieve HBV Cure (PL18) |
Dr Dimitar GOTCHEV
(ARBUTUS BIOPHARMA, Doylestown, United States) |
| 17:30 | Coffee Break |
|
| 18:00 | Direct-Acting Antivirals with a Targeted Protein Degradation Mechanism (PL19) |
Prof. Priscilla YANG
(STANFORD UNIVERSITY, Stanford, United States) |
| 18:30 | Discovery of Obeldesivir; Oral Prodrug of Nucleoside GS-441524 That Exhibits Antiviral Efficacy in SARS-CoV-2-Infected African Green Monkeys (PL20) |
Dr Rao KALLA
(GILEAD SCIENCES, Foster City, United States) |
| 19:00 | The Discovery of PAXLOVID (KL02) |
Dr Dafydd OWEN
(PFIZER, Cambridge, United States) |
| 20:00 | End of the Scientific Programme |
|
| 20:30 | Conference Dinner |
|
| Wednesday 31/01/2024 |
| 08:29 | Radical Intermediates in Complex Molecule Synthesis |
|
| Session Chair |
Prof. Nina HARTRAMPF
(UNIVERSITY OF ZURICH, Zürich, Switzerland) |
| 08:30 | Light-Mediated Nickel Catalysis Enabled by Donor-Acceptor Ligands (PL21) |
Prof. Bart PIEBER (INSTITUTE OF SCIENCE AND TECHNOLOGY AUSTRIA (ISTA), Klosterneuburg, Austria)
(SOPLVIAS AG (WAS FUJIFILM)) |
| 09:00 | Recent Adventures in Catalysis and Beyond (PL22) |
Prof. Bill MORANDI
(ETH ZÜRICH, Zürich, Switzerland) |
| 09:30 | Coffee Break |
|
| 10:00 | Alkenes as Flexible Platforms for Asymmetric Transformations (PL23) |
Prof. Cristina NEVADO
(UNIVERSITY OF ZURICH, Zurich, Switzerland) |
| 10:30 | Attempts to Deliver on the Promise of Natural Product Synthesis (PL24) |
Prof. Ryan SHENVI
(SCRIPPS RESEARCH, La Jolla, United States) |
| 11:00 | Outdoor Networking Activities |
|
| 16:00 | Networking Break |
|
| 16:15 | AI for Medicinal Chemists: Novel Compounds Design and Retrosynthesis Prediction
o_BRCompany Workshop by Iktosc_BR |
Dr Quentin PERRON
(IKTOS, Paris, France) |
| 16:59 | Drug Discovery Tales I |
|
| Session Chair |
Dr Scott WOLKENBERG
(JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON, Spring House, United States) |
| 17:00 | NLRP3 Inhibitors for Neurodegenerative Disorders (OC01) |
Dr Oscar MAMMOLITI
(JANSSEN RESEARCH & DEVELOPMENT, Beerse, Belgium) |
| 17:30 | Discovery of a Bivalent Protein Kinase CK2 Inhibitor with Activity in Renal Cell Carcinoma (OC02) |
Dr Isabelle KRIMM
(CLB, Lyon, France) |
| 17:50 | Coffee Break |
|
| 18:20 | Discovery of BI 7446: A Potent Cyclic Dinucleotide Sting Agonist with Broad-Spectrum Variant Activity for the Treatment of Cancer (OC03) |
Dr Christian KUTTRUFF
(BOEHRINGER INGELHEIM PHARMA GMBH & CO. KG, Biberach, Germany) |
| 18:40 | Discovery of [18F]RoSMA-18-D6 for PET Imaging of Cannabinoid Type 2 Receptors (OC04) |
Dr Luca GOBBI
(F. HOFFMANN-LA ROCHE, Basel, Switzerland) |
| 19:00 | Selective Inhibition of Tead Transcription and Impact on the Up-Stream Effector Kinases of the Hippo Pathway to Halt Metastatic Colorectal Cancer Cell Growth (OC05) |
Prof. Maria Paola COSTI
(UNIVERSITY OF MODENA AND REGGIO EMILIA, Modena, Italy) |
| 19:20 | Poster Session 2 (even numbers) |
|
| 20:30 | End of the Poster Session |
|
| Thursday 01/02/2024 |
| 08:29 | Cryo-EM: Applications for Structure-Based Drug Discovery |
|
| Session Chair |
Dr Katharina DÜRR
(OMASS THERAPEUTICS, Oxford, United Kingdom) |
| 08:30 | Deep Learning-Driven De Novo Drug Design Based on Gastric Proton Pump Structure (PL25) |
Prof. Kazuhiro ABE
(NAGOYA UNIVERSITY, Nagoya, Japan) |
| 09:00 | Cryo-EM Enables Structure-Based Drug Design for Membrane Protein Targets at BI (PL26) |
Dr Rebecca EBENHOCH
(BOEHRINGER INGELHEIM, Biberach, Germany) |
| 09:30 | Coffee Break |
|
| 10:00 | Single Particle CryoEM at 200 kV & Itchy GPRCs (PL27) |
Prof. Jonathan F. FAY
(UNIVERSITY OF NORTH CAROLINA CHAPEL HILL, Chapel Hill, United States) |
| 10:30 | Examples from Structure-Based Drug Discovery Using Cryo-EM at MSD (PL28) |
Dr Harini KRISHNAMURTHY
(MERCK, SHARP & DOHME, Blue Bell, United States) |
| 11:00 | Outdoor Networking Activities |
|
| 16:00 | Networking Break |
|
| 16:59 | Drug Discovery Tales II |
|
| Session Chair |
Dr Scott WOLKENBERG
(JANSSEN PHARMACEUTICAL COMPANIES OF JOHNSON & JOHNSON, Spring House, United States) |
| 17:00 | Discovery of a Novel Oral NO- and Heme-Independent sGC Activator Runcaciguat (BAY 1101042) (OC06) |
Dr Michael G. HAHN
(BAYER AG PHARMACEUTICALS, Wuppertal, Germany) |
| 17:30 | Heterocyclic Compounds as Delta-5 Desaturase Inhibitors (OC07) |
Dr Ana MINATTI
(AMGEN INC, Copenhagen, Denmark) |
| 18:00 | Coffee Break |
|
| 18:30 | Novel Approaches to Molecular Glue Discovery: Design of Clinical Candidate NVP-DKY709 an IKZF2 Degrader by Re-Programming of CRBN Selectivity and Screening for Cooperativity Using DNA Encoded Libraries (OC8) |
Dr Frédéric ZECRI
(NOVARTIS, Cambridge, United States) |
| 19:00 | Discovery of LY3154885, a Dopamine D1 Receptor Positive Allosteric Modulator with an Improved Drug-Drug Interaction Risk Profile (OC09) |
Dr Erik HEMBRE
(ELI LILLY AND COMPANY, Indianapolis, United States) |
| 19:30 | Site-Selective C—H Oxidations for Late-Stage Functionalizations (KL03) |
Prof. M. Christina WHITE
(UNIVERSITY OF ILLINOIS URBANA-CHAMPAIGN, Urbana, United States) |
| 20:30 | Closing Remarks |
|
